UNSPSC 51172425: Atropine/difenoxin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA208. This VA Drug Class (GA208) classifies this compound as belonging to the group ANTIDIARRHEAL AGENTS.

UNSPSC 51172425 Atropine/difenoxin, a Commodity code, represents pharmaceutical active ingredients and finished products that state and local procurement offices buy for corrections, public health, and pharmacy benefit programs. Recent solicitations show demand across offender drug testing programs, therapeutic pharmacy initiatives, and cooperative purchasing agreements for generic pharmaceuticals and over-the-counter products. The work spans specimen-collection-lab services requiring specific drug-testing panels (five-panel and six-panel screens with LC/MS/MS or GC/MS confirmation), direct-to-manufacturer prescription programs operated by state health agencies, and wholesale distribution contracts administered through multistate cooperative purchasing vehicles.

Issuing bodies include county corrections departments (Collin County Community Supervision and Corrections Department), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving participating state and local government facilities in Minnesota and Oregon). Recent activity spans Texas and Minnesota, with the Texas HHS RFI suggesting broader state interest in direct pharmaceutical contracting. Representative recent opportunities include Collin County's RFP 2026-327 for offender specimen collection and drug testing services (RFP due July 23, 2026, estimated contract value $600,000 over two years with optional three one-year renewals), the Texas HHS Commission's Request for Information HHS0017013 on direct-to-manufacturer prescriptions (posted April 3, 2026, exploratory phase with no award value disclosed), and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products (due March 26, 2026, two-year initial term with optional extensions, no specific award value disclosed but 3 percent administrative fee on all purchases).